Yu Shyr

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations

Medicine, Genetics, Oncology +17

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Brian D. Lehmann, Bojana Jovanović, Xi Chen et al. · PLoS ONE · 2016 · 1.4K citations · Full text

Medicine, Cancer Biology, Oncology +17